The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the Midwest CEPAC process, and Find out how topics are selected.
Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the Midwest CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the Midwest CEPAC. For more information about past and other upcoming meetings, see the box to the right.
The Midwest CEPAC will convene to deliberate on ICER's report on voretigene neparvovec.
ICER will develop a report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Spark Therapeutics), a potentially one-time gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Voretigene neparvovec is the first gene therapy to be submitted for approval by the US Food and Drug Administration (FDA).
Date of review: January 2018View materials